Last reviewed · How we verify
NCT06643416
Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Phase 3 trial testing Timolol 0.5% eye drops and betamethasone valerate 0.1% cream in Paronychia in 40 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Queen Mary Hospital, Hong Kong |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 9 October 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Timolol 0.5% eye drops and betamethasone valerate 0.1% cream — full drug profile →
- Betamethasone valerate 0.1% cream
Conditions studied
- Paronychia — all drugs for Paronychia →
- EGFR-TKI — all drugs for EGFR-TKI →
- ALK-TKI — all drugs for ALK-TKI →
Sponsor
Queen Mary Hospital, Hong Kong
Who can join
18 and older, any sex, with Paronychia or EGFR-TKI. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06643416
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Paronychia
Currently open trials in the same condition.
- NCT05639933 — Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Assoc · Phase 2 · recruiting
Other Queen Mary Hospital, Hong Kong trials
Trials by the same sponsor.
- NCT07461064 — HIFU vs Observation for LSIL of Cervix: A Randomized Controlled Trial · NA · not yet recruiting
- NCT06178471 — Safety, Feasibility and Clinical Utility of Critical Care Transesophageal Echocardiography in Hong Kong · not yet recruiting
- NCT06037356 — PUL vs TURP in BPH Patients With Urinary Retention · NA · recruiting
- NCT06551337 — Vitamin D Replacement in Bronchiectasis · Phase 4 · recruiting
- NCT06094387 — The Use of Thrombin Generation Assay in Detection of Central Line Related Thrombosis (CRT) in Critically Ill Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06643416 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Queen Mary Hospital, Hong Kong
- Last refreshed: 18 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06643416.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing